Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Bristol-Myers Squibb Earnings Preview: What to Expect

Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. With a market cap of $120.9 billion, the company offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. BMY is expected to release its Q1 2026 earnings on Thursday, Apr. 30, before the market opens.

Ahead of the event, analysts expect the company’s EPS to be $1.46 on a diluted basis, down 18.9% from $1.80 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in each of its last four quarters.

Fundamentals

See More
  • Market Capitalization, $K 120,870,712
  • Shares Outstanding, K 2,041,735
  • Annual Sales, $ 48,194 M
  • Annual Income, $ 7,054 M
  • EBIT $ 12,645 M
  • EBITDA $ 16,656 M
  • 60-Month Beta 0.27
  • Price/Sales 2.44
  • Price/Cash Flow 7.09
  • Price/Book 6.34

Options Overview Details

View History
  • Implied Volatility 30.47% (+0.27%)
  • Historical Volatility 25.47%
  • IV Percentile 51%
  • IV Rank 28.27%
  • IV High 55.70% on 04/10/25
  • IV Low 20.52% on 12/31/25
  • Expected Move (DTE 1) 0.77 (1.31%)
  • Put/Call Vol Ratio 0.31
  • Today's Volume 6,694
  • Volume Avg (30-Day) 22,443
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 534,397
  • Open Int (30-Day) 561,158
  • Expected Range 58.46 to 60.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.46
  • Number of Estimates 10
  • High Estimate $1.59
  • Low Estimate $1.39
  • Prior Year $1.80
  • Growth Rate Est. (year over year) -18.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.45 +5.03%
on 03/24/26
62.22 -4.72%
on 04/01/26
-1.34 (-2.21%)
since 03/09/26
3-Month
53.54 +10.73%
on 01/21/26
62.89 -5.72%
on 03/02/26
+3.43 (+6.14%)
since 01/09/26
52-Week
42.52 +39.44%
on 10/29/25
62.89 -5.72%
on 03/02/26
+5.55 (+10.33%)
since 04/09/25

Most Recent Stories

More News
Bristol-Myers Squibb Earnings Preview: What to Expect

Bristol-Myers Squibb is approaching its first-quarter earnings release this month, and Wall Street is forecasting a double-digit percentage fall in earnings.

XLV : 149.87 (+0.13%)
$SPX : 6,816.53 (+0.50%)
BMY : 59.40 (+0.34%)
Gilead to Acquire Tubulis for Up to $5 Billion to Expand Cancer Drug Pipeline

Gilead Sciences ($GILD) said Tuesday it will acquire Germany-based Tubulis GmbH for up to $5 billion, including $3.15 billion upfront and up to $1.85 billion in milestone payments, as the company expands...

GILD : 142.53 (+0.70%)
BMY : 59.40 (+0.34%)
AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know

AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know

AMN : 18.47 (-2.69%)
ABBV : 212.98 (+0.66%)
NVAX : 8.55 (+1.54%)
DVA : 150.95 (+1.69%)
BMY : 59.40 (+0.34%)
3 Value Stocks Walking a Fine Line

3 Value Stocks Walking a Fine Line

APAM : 37.01 (+0.57%)
UTZ : 7.57 (-0.13%)
BMY : 59.40 (+0.34%)
Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years

New survey, guided by patient advocacy input, seeks to elevate lived experience and community voice to better understand challenges in multiple myeloma care

BMY : 59.40 (+0.34%)
1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm

1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm

TLYS : 5.12 (+8.94%)
UTHR : 578.18 (-0.60%)
BMY : 59.40 (+0.34%)
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Trial met its primary endpoint, demonstrating clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 ...

BMY : 59.40 (+0.34%)
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

High treatment completion and no discontinuations due to lack of efficacy observed across faster and slower switch strategies

BMY : 59.40 (+0.34%)
Stocks making big moves yesterday: Robinhood, Payoneer, Micron, Limbach, and Bristol-Myers Squibb

Stocks making big moves yesterday: Robinhood, Payoneer, Micron, Limbach, and Bristol-Myers Squibb

LMB : 84.48 (+0.61%)
PAYO : 4.57 (-1.72%)
MU : 407.50 (+0.19%)
HOOD : 71.13 (-0.97%)
BMY : 59.40 (+0.34%)
Why Bristol-Myers Squibb (BMY) Stock Is Up Today

Why Bristol-Myers Squibb (BMY) Stock Is Up Today

BMY : 59.40 (+0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers...

See More

Key Turning Points

3rd Resistance Point 61.29
2nd Resistance Point 60.26
1st Resistance Point 59.73
Last Price 59.38
1st Support Level 58.17
2nd Support Level 57.14
3rd Support Level 56.61

See More

52-Week High 62.89
Last Price 59.38
Fibonacci 61.8% 55.11
Fibonacci 50% 52.70
Fibonacci 38.2% 50.30
52-Week Low 42.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.